Inovio Pharmaceuticals
Innovative DNA medicines and vaccines to combat infectious diseases and cancer.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | $30.0m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (76 %) | 478 % | (92 %) | (74 %) | (50 %) | 14909 % | 348 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (16528 %) | (2617 %) | (15111 %) | (49979 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (17110 %) | (2727 %) | (16240 %) | (49254 %) | (84514 %) | (583 %) | (75 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 14044 % | 1829 % | 10418 % | 34727 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
INOVIO is a clinical-stage biotechnology company dedicated to developing novel DNA medicines and vaccines aimed at treating and preventing infectious diseases and cancer. The company leverages its proprietary investigational delivery devices to ensure optimal cellular uptake of its DNA medicines. INOVIO primarily serves patients suffering from HPV-related diseases, various cancers, and infectious diseases. Operating in the biopharmaceutical market, INOVIO collaborates extensively with industry, academia, and government entities to drive innovation and advance its promising DNA medicine candidates. The business model focuses on research and development, clinical trials, and eventual commercialization of its DNA-based therapies. Revenue is generated through partnerships, grants, and future product sales.
Keywords: DNA medicines, vaccines, infectious diseases, cancer, HPV, biotechnology, clinical-stage, biopharmaceutical, innovation, cellular uptake.
Tech stack
Investments by Inovio Pharmaceuticals
Edit
